These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27311820)

  • 1. Melanin and neuromelanin binding of drugs and chemicals: toxicological implications.
    Karlsson O; Lindquist NG
    Arch Toxicol; 2016 Aug; 90(8):1883-91. PubMed ID: 27311820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanin affinity and its possible role in neurodegeneration.
    Karlsson O; Lindquist NG
    J Neural Transm (Vienna); 2013 Dec; 120(12):1623-30. PubMed ID: 23821370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Sepia melanin as a PD model to describe the binding characteristics of neuromelanin - A critical review.
    Schroeder RL; Double KL; Gerber JP
    J Chem Neuroanat; 2015; 64-65():20-32. PubMed ID: 25681296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention of the cyanobacterial neurotoxin beta-N-methylamino-l-alanine in melanin and neuromelanin-containing cells--a possible link between Parkinson-dementia complex and pigmentary retinopathy.
    Karlsson O; Berg C; Brittebo EB; Lindquist NG
    Pigment Cell Melanoma Res; 2009 Feb; 22(1):120-30. PubMed ID: 19154235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ
    Med Hypotheses; 2005; 65(4):791-6. PubMed ID: 15949901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
    Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
    J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
    Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromelanin and its possible protective and destructive properties.
    Lindquist NG; Larsson BS; Lydén-Sokolowski A
    Pigment Cell Res; 1987; 1(3):133-6. PubMed ID: 3334086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy.
    Enochs WS; Nilges MJ; Swartz HM
    J Neurochem; 1993 Jul; 61(1):68-79. PubMed ID: 8390568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between chemicals and melanin.
    Larsson BS
    Pigment Cell Res; 1993 Jun; 6(3):127-33. PubMed ID: 8234197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical signs of Parkinson's disease: A possible association of Parkinson's disease with skin and hair features.
    Jucevičiūtė N; Banaitytė I; Vaitkus A; Balnytė R
    Med Hypotheses; 2019 Jun; 127():100-104. PubMed ID: 31088630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron, melanin and dopamine interaction: relevance to Parkinson's disease.
    Ben-Shachar D; Youdim MB
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):139-50. PubMed ID: 8416600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional effects of neuromelanin and synthetic melanin in model systems.
    Double KL
    J Neural Transm (Vienna); 2006 Jun; 113(6):751-6. PubMed ID: 16755379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma.
    Leupold D; Szyc L; Stankovic G; Strobel S; Völker HU; Fleck U; Müller T; Scholz M; Riederer P; Monoranu CM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31208049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.